• Title of article

    Prevalence and risk factors of radiation-induced growth hormone deficiency in childhood cancer survivors: A systematic review

  • Author/Authors

    Mulder، نويسنده , , Renée L. and Kremer، نويسنده , , Leontien C.M. and Santen، نويسنده , , Hanneke M. van and Ket، نويسنده , , Jan Lucas and Trotsenburg، نويسنده , , A.S. Paul van and Koning، نويسنده , , Caro C.E. and Meeteren، نويسنده , , Antoinette Y.N. Schouten-van and Caron، نويسنده , , Huib N. and Neggers، نويسنده , , Sebastian J.C.M.M. and Dalen، نويسنده , , Elvira C، نويسنده ,

  • Issue Information
    روزنامه با شماره پیاپی سال 2009
  • Pages
    17
  • From page
    616
  • To page
    632
  • Abstract
    SummaryBackground hormone deficiency (GHD) is usually the first and most frequent endocrine problem occurring after cranial radiotherapy (CRT). The aim of this systematic review was to evaluate the existing evidence of the prevalence and risk factors of radiation-induced GHD in childhood cancer survivors. s E, EMBASE and CENTRAL were searched for studies reporting on radiation-induced GHD in childhood cancer survivors. Information about study characteristics, prevalence and risk factors was abstracted and the quality of each study was assessed. A meta-regression analysis was performed. s evalence of radiation-induced GHD was estimated in 33 studies. Most studies had methodological limitations. The prevalence varied considerably between 0% and 90.9%. Selecting only the studies with adequate peak GH cut-off limits (<5 μg/L) resulted in 3 studies. In these studies the prevalence ranged from 29.0% to 39.1%, with a pooled prevalence of 35.6%. Higher CRT dose and longer follow-up time have been suggested to be the main risk factors of GHD by studies included in this review. The meta-regression analysis showed that the wide variation in the prevalence of GHD could be explained by differences in maximal CRT dose. sions a frequent consequence after CRT in childhood cancer survivors. The prevalence of radiation-induced GHD ranged from 29.0% to 39.1% when selecting only studies with adequate peak GH cut-off limits. Higher CRT dose and longer follow-up time are the main risk factors. More well-designed studies are needed to accurately estimate the prevalence of GHD and to define the exact CRT threshold dose.
  • Keywords
    Growth hormone deficiency , Cranial radiotherapy , systematic review , Childhood cancer survivors
  • Journal title
    Cancer Treatment Reviews
  • Serial Year
    2009
  • Journal title
    Cancer Treatment Reviews
  • Record number

    1835318